Single cell antibody discovery using ‘Islands of Automation’

Eli Lilly, a global healthcare leader, has implemented a next generation research (NGR) initiative to improve the value output of the R&D portfolio in cell line development (CLD). One of the NGR pillars focuses on decreasing the timeline to bring medicines to patients. Lilly has invested in ‘Islands of Automation’ to advance the B cell antibody discovery platform at the Lilly Biotechnology Center in San Diego with the goal of significantly increasing throughput and reducing project timelines.

In this webinar, Paul Anderson, Director - Biologics Discovery Automation at Eli Lilly will focus on the automated systems that have been developed as part of this platform. This highly automated approach to antibody discovery has enabled Lilly to meet aggressive timelines and dramatically increase throughput while allowing flexibility for future changes to its process.

Key learning objectives:

Monoclonal antibody discovery from single B cells.
Modular automated systems that allow for maximum flexibility to support several workflows in addition to monoclonal antibody discovery.
Automated system design and optimization.

Who should attend?

Research and pharma professionals working in cell line development, biologics and biotherapeutics that are seeking to improve reproducibility, efficiency, and data integrity in their campaigns and workflows.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.